Here’s a novel idea for the weight-loss drug market: a subscription. Novo Nordisk A/S (NVO) announced on Tuesday that it’s launching the first multi-month subscription program for its blockbuster obesity treatment Wegovy (semaglutide). The goal? To make the price tag less of a shock for patients who pay for it themselves and, hopefully, to keep them on the treatment longer.
Think of it like your streaming service, but for a medication that requires a prescription. The program, which starts on March 31, 2026, lets eligible patients get the FDA-approved treatment through select online telehealth providers for a fixed monthly fee. No more guessing what next month’s bill will look like.
This news follows another recent development for Wegovy. Earlier in March, the FDA gave the green light to a higher-dose version, Wegovy HD (semaglutide injection 7.2 mg). This is for patients who have already been handling the standard 2.4 mg dose but need an extra push for more weight reduction. So, Novo Nordisk is expanding its portfolio while also trying to make the existing options more accessible.
How the Subscription Pricing Works
So, what’s the damage? Novo Nordisk has set up a tiered pricing structure. The basic idea is simple: commit for longer, pay less each month. For the Wegovy injections, the monthly cost ranges from $329 if you sign up for a three-month plan down to $249 if you lock in for a full year. Over 12 months, that top-tier plan could save a patient up to $1,200 compared to shorter commitments.
If you prefer the pill, there’s a plan for the oral version too, with prices between $289 and $249 per month, offering potential annual savings of up to $600. The company also notes there are lower-dose options available at reduced rates. It’s worth mentioning that some separate promotional pricing is floating around, but those are limited-time offers and different from the subscription plans. Those deals may vary depending on where you look and are set to expire later in 2026.
Getting It Through Your Screen
You won’t be signing up directly on Novo Nordisk’s website. The subscription program is being rolled out through telehealth partners. At launch, it will be available through providers like Ro, WeightWatchers, and LifeMD Inc (LFMD). Other platforms, including Hims & Hers Health Inc. (HIMS) and Sesame, are expected to join the party later.
Because each telehealth platform might have its own rules, Novo Nordisk says patients should contact the providers directly to check if they’re eligible and to get the specific enrollment details. It’s not a one-size-fits-all portal.
The Bigger Picture: Access and Adherence
Why go through all this trouble? Novo Nordisk is framing this as more than just a pricing gimmick. The company emphasizes that obesity is a chronic condition that needs long-term management under a doctor’s care. The hope is that by smoothing out the cost with a predictable subscription, patients are more likely to stick with the treatment over time, rather than stopping because of financial surprises.
It’s important to remember that this subscription is one path among many. Wegovy is still available the old-fashioned way through more than 70,000 pharmacies across the U.S. and NovoCare Pharmacy. And for patients with commercial insurance, existing savings programs can bring the cost down to as little as $25 a month. The subscription model is specifically targeting the self-pay crowd.
The launch of this program comes at a dynamic time for the GLP-1 drug market. Just last week, reports indicated that at least six pharmaceutical companies in India have introduced generic versions of Novo Nordisk’s Ozempic and Wegovy. This follows the expiration of the Indian patent for semaglutide. These generics are hitting the market at prices roughly 70% lower than the branded versions, creating a new competitive landscape in certain regions.
As for the stock, shares of Novo Nordisk were up 1.45% at $35.80 at the time of the initial report on Tuesday.
